Flecainide acetate in the treatment of resistant supraventricular arrhythmias.
Thirty-one patients with a variety of supraventricular tachyarrhythmias resistant to conventional anti-arrhythmic therapy were treated with flecainide acetate, a new class Ic antiarrhythmic drug. The mean follow-up period was 7 months. Control was attained in 19 patients (62%) initially, and the long-term success rate was 39%. In 7 of the 19 controlled patients the drug was subsequently discontinued because of major side-effects, which included negative inotropism and pro-arrhythmia. The mechanisms and implications of these side-effects are reviewed.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003864:Depression, Chemical; D004562:Electrocardiography; D005260:Female; D005424:Flecainide / Q000009:adverse effects / Q000627:therapeutic use*; D006329:Heart Conduction System / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D013617:Tachycardia, Supraventricular / Q000188:drug therapy*; D013997:Time Factors
D005424:Flecainide